On May 31, 2024, Kardium Inc., a Vancouver-based medical solutions company, raised USD $104 million in a financing round led by Fidelity Management & Research Company with follow-on participation by funds and accounts advised by T. Rowe Price Associates, Inc. and T. Rowe Price Investment Management, Inc. as well as new investor Durable Capital Partners LP.
This investment enables Kardium to complete the PULSAR clinical study, achieve regulatory approvals, grow their manufacturing team and to build a clinical support and commercial team to commercially launch the Globe System.
The Globe System has been developed for the treatment of atrial fibrillation – it consists of a single sophisticated catheter with a 122-electrode array and advanced software that enable rapid pulmonary vein isolation, high-definition mapping, and the ability to ablate anywhere in the atrium.
Fasken advised Kardium Inc. with a team led by Shahrooz Nabavi and Katie Chandler and included Brock Euper.
Jurisdictions
- Canada
- United States
